A phase transition caught in mid-course: independent and concomitant analyses of the monoclinic and triclinic structures of ((n)Bu(4)N)[Co(orotate)(2)(bipy)]·3H(2)O

相变过程中的意外发现:(n)Bu(4)N)[Co(乳清酸)2(联吡啶)]·3H2O 的单斜和三斜结构的独立和伴随分析

阅读:2

Abstract

The preparation and characterization of the (n)Bu(4)N(+) salts of two bis-orotate(2-) complexes of cobalt, namely bis(tetra-n-butylammonium) diaquabis(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-ide-6-carboxylato-κ(2)N(1),O(6))cobalt(II) 1.8-hydrate, (C(16)H(36)N)(2)[Co(C(5)H(2)N(2)O(4))(2)(H(2)O)(2)]·1.8H(2)O, (1), and tetra-n-butylammonium (2,2'-bipyridine-κ(2)N,N')bis(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-ide-6-carboxylato-κ(2)N(1),O(6))cobalt(III) trihydrate, (C(16)H(36)N)[Co(C(5)H(2)N(2)O(4))(2)(C(10)H(8)N(2))]·3H(2)O, (2), are reported. The Co(III) complex, (2), which is monoclinic at room temperature, presents a conservative single-crystal-to-single-crystal phase transition below 200 K, producing a triclinic twin. The transition, which involves a conformational change in one of the (n)Bu groups of the cation, is reversible and can be cycled. Both end phases have been characterized structurally and the system was also characterized structurally in a two-phase intermediate state, using single-crystal diffraction techniques, with both the monoclinic and triclinic phases present. Thermal analysis allows a rough estimate of the small energy content, viz. 0.25 kJ mol(-1), for both the monoclinic-to-triclinic transformation and the reverse transition, in agreement with the nature of the structural changes involving only the (n)Bu(4)N(+) cation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。